Literature DB >> 15845113

Readmission patterns in patients with chronic obstructive pulmonary disease, chronic heart failure and diabetes mellitus: an administrative dataset analysis.

C Brand1, V Sundararajan, C Jones, A Hutchinson, D Campbell.   

Abstract

Comprehensive disease management programmes for chronic disease aim to improve patient outcomes and reduce health-care utilization. Readmission rates are often used as an outcome measure of effectiveness. This study aimed to document readmission rates, and risk for early and late readmission, for patients discharged from the Royal Melbourne Hospital with a disease diagnosis of chronic heart failure (CHF), chronic obstructive pulmonary disease (COPD) or diabetes mellitus compared to those with other general medical conditions. Eighty five (8.6%) of patients were readmitted within 28 days and 183 (20.8%) were readmitted between 29 and 180 days. No risk factors for early readmission were identified. Patients with a primary disease diagnosis of CHF and COPD are at increased risk of late readmissions (29-180 days).

Entities:  

Mesh:

Year:  2005        PMID: 15845113     DOI: 10.1111/j.1445-5994.2005.00816.x

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  8 in total

1.  Hospital readmissions after elective lower extremity vascular procedures.

Authors:  Todd R Vogel; Jamie B Smith; Robin L Kruse
Journal:  Vascular       Date:  2017-09-20       Impact factor: 1.285

2.  Predicting 30-Day Readmission Risk for Patients With Chronic Obstructive Pulmonary Disease Through a Federated Machine Learning Architecture on Findable, Accessible, Interoperable, and Reusable (FAIR) Data: Development and Validation Study.

Authors:  Celia Alvarez-Romero; Alicia Martinez-Garcia; Jara Ternero Vega; Pablo Díaz-Jimènez; Carlos Jimènez-Juan; María Dolores Nieto-Martín; Esther Román Villarán; Tomi Kovacevic; Darijo Bokan; Sanja Hromis; Jelena Djekic Malbasa; Suzana Beslać; Bojan Zaric; Mert Gencturk; A Anil Sinaci; Manuel Ollero Baturone; Carlos Luis Parra Calderón
Journal:  JMIR Med Inform       Date:  2022-06-02

3.  Postpartum Readmissions Among Women With Diabetes.

Authors:  Mirella Mourad; Timothy Wen; Alexander M Friedman; Jacqueline Y Lonier; Mary E D'Alton; Noelia Zork
Journal:  Obstet Gynecol       Date:  2020-01       Impact factor: 7.623

Review 4.  Respiratory rehabilitation after acute exacerbation of COPD may reduce risk for readmission and mortality -- a systematic review.

Authors:  Milo A Puhan; Madlaina Scharplatz; Thierry Troosters; Johann Steurer
Journal:  Respir Res       Date:  2005-06-08

Review 5.  Effectiveness of interventions utilising telephone follow up in reducing hospital readmission within 30 days for individuals with chronic disease: a systematic review.

Authors:  Amanda Jayakody; Jamie Bryant; Mariko Carey; Breanne Hobden; Natalie Dodd; Robert Sanson-Fisher
Journal:  BMC Health Serv Res       Date:  2016-08-18       Impact factor: 2.655

6.  Unplanned readmission or death after discharge for Aboriginal and non-Aboriginal people with chronic disease in NSW Australia: a retrospective cohort study.

Authors:  Amanda Jayakody; Christopher Oldmeadow; Mariko Carey; Jamie Bryant; Tiffany Evans; Stephen Ella; John Attia; Rob Sanson-Fisher
Journal:  BMC Health Serv Res       Date:  2018-11-26       Impact factor: 2.655

7.  A three-step approach for the derivation and validation of high-performing predictive models using an operational dataset: congestive heart failure readmission case study.

Authors:  Samir E AbdelRahman; Mingyuan Zhang; Bruce E Bray; Kensaku Kawamoto
Journal:  BMC Med Inform Decis Mak       Date:  2014-05-27       Impact factor: 2.796

8.  Diagnosis-specific readmission risk prediction using electronic health data: a retrospective cohort study.

Authors:  Courtney Hebert; Chaitanya Shivade; Randi Foraker; Jared Wasserman; Caryn Roth; Hagop Mekhjian; Stanley Lemeshow; Peter Embi
Journal:  BMC Med Inform Decis Mak       Date:  2014-08-04       Impact factor: 2.796

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.